Story thread · 2 reports / 2 sources
Ventripoint Expands Subscription Access for FDA-Cleared AI Cardiac Imaging
thestar.com · 3h · first report
TORONTO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV: VPT; OTC: VPTDF), a leader in AI-assisted cardiac imaging, today announced the next phase of its commercial strategy for VMS+™ 4.0, its FDA-cleared platform that…
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.